Replies to post #251781 on Biotech Values

[DewDiligence]

PFE/BNTX—Flu-COVID combo vaccine—>insufficient immunogenicity against influenza B:

https://finance.yahoo.com/news/pfizer-biontech-mrna-based-combination-104500816.html

The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain, despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines,

…The companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.

This setback ought to be bullish for the flu/COVID combo vaccine programs from MRNA (#msg-174351482) and from SNY/NVAX (#msg-174392861).